Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma

16 Aug 2018

Abstract excerpt

The BTK inhibitor ibrutinib has demonstrated a remarkable therapeutic effect in mantle cell lymphoma (MCL). However, approximately one-third of patients do not respond to the drug initially. To identify the mechanisms underlying primary ibrutinib resistance in MCL, we analyzed the transcriptome changes in ibrutinib-sensitive and ibrutinib-resistant cell lines on ibrutinib treatment. We found that MYC gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Galectins and Cancer Biology
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30115641
DOI: 10.1182/bloodadvances.2018016048

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphomaPMID 30115641Read ↗

The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphomaSemantic proximity Read ↗

Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphomaSemantic proximity Read ↗

Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.Semantic proximity Read ↗

Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma.Semantic proximity Read ↗

Cyclin-Dependent Kinase 5 Contributes to Bruton’s Tyrosine Kinase Inhibitor Resistance via the IRE1α/XBP1 Axis in Mantle Cell LymphomaSemantic proximity Read ↗

Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myelomaSemantic proximity Read ↗

The Impact of the BCR Phenotype of Large B-cell Lymphoma on Ibrutinib Sensitivity.Semantic proximity Read ↗

Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells.Semantic proximity Read ↗

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphomaSemantic proximity Read ↗

Inhibition of BIRC5 and MCL1 as a potential treatment strategy to overcome drug resistance in Mantle Cell LymphomaSemantic proximity Read ↗

Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphomaSemantic proximity Read ↗

Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.